Beximco Pharmaceuticals Limited’s Stock Is Buy After Reaching 52-Week High

 Beximco Pharmaceuticals Limited's Stock Is Buy After Reaching 52 Week High

The stock of Beximco Pharmaceuticals Limited (LON:BXP) hit a new 52-week high and has GBX 60.37 target or 8.00% above today’s GBX 55.90 share price. The 5 months bullish chart indicates low risk for the GBX 33.33 billion company. The 1-year high was reported on Nov, 23 by Barchart.com. If the GBX 60.37 price target is reached, the company will be worth GBX 2.67 billion more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 0.72% or GBX 0.4 on November 23, hitting GBX 55.9. About 245,109 shares traded hands or 210.37% up from the average. Beximco Pharmaceuticals Limited (LON:BXP) has risen 114.84% since April 26, 2016 and is uptrending. It has outperformed by 109.51% the S&P500.

Another recent and important Beximco Pharmaceuticals Limited (LON:BXP) news was published by Uk.Finance.Yahoo.com which published an article titled: “Beximco Pharmaceuticals Limited (BXP.L)” on March 30, 2014.

Beximco Pharmaceuticals Limited is engaged in the manufacturing and marketing of generic pharmaceuticals formulation products, including intravenous fluids and active pharmaceutical ingredients (APIs). The company has a market cap of 33.33 billion GBP. The Firm also provides contract manufacturing services. It has a 0.12 P/E ratio. The Firm produces approximately 300 generic medicines, which are available in over 500 different presentations and the portfolio encompasses various key therapeutic categories, including antibiotics, analgesics, anti-diabetic, respiratory, cardiovascular, central nervous system, dermatology and gastrointestinal.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment